Leukemia
In this section, we cover the latest in cutting-edge leukemia news and research. Leukemias are a group of diseases that result from the unregulated clonal proliferation of cells secondary to genetic abnormalities in hematopoietic cells. Compared to normal cells, a high rate of proliferation and low rate of apoptosis offers leukemic cells a growth advantage.
Advertisement
Advertisement
Acute Lymphoblastic Leukemia
Measurable residual disease has a prominent role in risk assessment, prognosis, and management decisions in T-ALL and B-ALL.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
CTD402 will be studied in a single-arm, open-label, phase 1b/2 trial with a simplified dose-finding design.
The approval is based on the E1910 trial, which compared blinatumomab and consolidation chemotherapy with chemotherapy alone.
Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
The US cancer mortality rate has declined by 34%, but the incidence of leukemia and other malignancies is increasing.
Acute Myeloid Leukemia
A systemic review found that 21 of 90 randomized controlled trials for AML reported on patients' race and ethnicity.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
The trial will evaluate the safety, optimal dosing, and CR rate and duration of Actimab-A, venetoclax, and ASTX-727 in AML.
Clinical development of AUTX-703 is planned to begin in the first quarter of 2025.
The phase 2 prospective trial with these results also evaluated overall survival, nonrelapse mortality, and relapse rates.
The amended protocol includes reducing the size of the MIRACLE trial by approximately 10%.
Chronic Lymphocytic Leukemia
Adam Kittai, MD, shares recent studies in CLL he is most excited about, including the AMPLIFY and TRANSCEND 004 trials.
The several considerations involved with these agent classes make discussions with patients of treatment decisions crucial.
BTKi/BCL2i combinations may change how CLL treatment is offered over a patient’s lifespan, said Kerry Rogers, MD.
David Russler-Germain, MD, PhD, joins the hosts of “Blood Cancer Talks” to highlight research in lymphoma and CLL.
Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.
Chronic Myeloid Leukemia
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
In a phase 1/2 trial the oral BCR-ABL1 TK inhibitor had effect even in patients with ponatinib-resistant disease.
ASC4FIRST Trial: Asciminib Shows Favorable Safety, Efficacy Versus Investigator-Selected TKIs in CML
Asciminib showed superior safety and efficacy compared with standard-of-care, second-generation, investigator-selected TKIs.
Pirtobrutinib cut disease progression/death risk by 46% vs IdealaR/BR in heavily pretreated relapsed/refractory CLL/SLL.
The US cancer mortality rate has declined by 34%, but the incidence of leukemia and other malignancies is increasing.
A real-world study found blinatumomab plus ponatinib as more likely to be effective if used in earlier lines of therapy.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.